Nuvectis Pharma sets up $200 million at-the-market equity program with Jefferies

• Nuvectis Pharma set up an at-the-market equity offering program to sell common stock from time to time through Jefferies.
• Program to be conducted under a new Form S-3 shelf registration statement covering USD 200 million of securities.
• Jefferies to earn up to 3% of gross proceeds on shares sold under the sales agreement.
• Prior at-the-market program tied to a February 13, 2026 prospectus supplement was terminated on July 20, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvectis Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-099712), on August 21, 2026, and is solely responsible for the information contained therein.